scispace - formally typeset
T

Terho Lehtimäki

Researcher at University of Tampere

Publications -  1375
Citations -  129159

Terho Lehtimäki is an academic researcher from University of Tampere. The author has contributed to research in topics: Population & Genome-wide association study. The author has an hindex of 142, co-authored 1304 publications receiving 106981 citations. Previous affiliations of Terho Lehtimäki include Boston University & National Institutes of Health.

Papers
More filters
Journal ArticleDOI

Upstream Transcription Factor 1 (USF1) Polymorphisms Associate with Alzheimer's Disease-related Neuropathological Lesions: Tampere Autopsy Study

TL;DR: USF1 has an independent but gender‐ and age‐associated effect on AD‐related brain lesion development, and younger USF1 CCGCAC carriers were more likely to have non‐neuritic and diffuse SP and had lower NFT prevalence among 65+ year‐olds.
Journal ArticleDOI

Angiotensin-converting enzyme gene polymorphism is associated with coronary heart disease in non—insulin-dependent diabetic patients evaluated for 9 years

TL;DR: The hypothesis that the ACE I/D polymorphism is an important and independent risk factor for CHD in patients with non-insulin-dependent diabetes mellitus (NIDs) is supported.
Journal ArticleDOI

Suppression of immune system genes by methylprednisolone in exacerbations of multiple sclerosis. Preliminary results.

TL;DR: The suppression of expression of genes associated with T-cell differentiation and antigen-specific T- cell activation detected in this study may contribute to the beneficial effect of MP in relapses of MS.
Journal ArticleDOI

High serum n6 fatty acid proportion is associated with lowered LDL oxidation and inflammation: The Cardiovascular Risk in Young Finns Study

TL;DR: Findings at the population level suggest that PUFAs are negatively and SFAs and MUFAs positively related with LDL oxidation and inflammation; these conclusions are in line with previous observations linking PUF as, particularly n6PUFAs, with lower CVD risk, andSFAs with increased risk.